August 30, 2014 1:39 PM ET

Pharmaceuticals

Company Overview of Zydus Pharmaceuticals (USA) Inc.

Company Overview

Zydus Pharmaceuticals (USA) Inc. develops, manufactures, and sells generic pharmaceutical products. It offers generic and reference products in tablet, capsule, soft gel, sterile liquid, injectable, inhaler, topical, and trans-dermal patch dosage forms. The company was incorporated in 2003 and is based in Pennington, New Jersey with locations in Memphis, Tennessee; and Ahmadabad, Vadodara, and Ankleshwar, India. Zydus Pharmaceuticals (USA) Inc. operates as a subsidiary of Cadila Healthcare Limited.

73 Route 31 North

Suite 103

Pennington, NJ 08534

United States

Founded in 2003

Phone:

609-730-1900

Fax:

609-730-1998

Key Executives for Zydus Pharmaceuticals (USA) Inc.

Chief Executive Officer
Compensation as of Fiscal Year 2014.

Zydus Pharmaceuticals (USA) Inc. Key Developments

Cadila Healthcare and Zydus Pharmaceuticals (USA), Inc. Enter into Settlement Agreement with Depomed on Gralise

Cadila Healthcare and Zydus Pharmaceuticals (USA) Inc. have entered into a settlement agreement with Depomed Inc. to settle their ongoing patent infringement litigation related to Gralise (gabapentin) 300 mg and 600 mg tablets. The settlement permits Cadila and Zydus to begin selling generic versions of Gralise on January 1, 2024, or earlier under certain circumstances. The agreement is subject to review by the US Department of Justice and the Federal Trade Commission, and entry of an order dismissing the litigation by the US District Court for the District of New Jersey.

Warner Chilcott Company Announces Tentative Agreement with Zydus Pharmaceuticals USA Inc. and Cadila Healthcare Limited to Settle Asacol HD Patent Challenge Litigation

Actavis plc announced that it its subsidiary, Warner Chilcott Company, LLC, has entered into an agreement in principle with Zydus Pharmaceuticals USA Inc. and Cadila Healthcare Limited to settle all outstanding patent litigation related to Zydus' generic version of Asacol(R) HD (mesalamine) delayed-release tablets. The agreement remains subject to preparation and execution of definitive documentation. Under the terms of the agreement in principle, Warner Chilcott Company will grant Zydus a royalty-bearing license to market its generic Asacol(R) HD beginning on November 15, 2015 or earlier under certain circumstances, following receipt by Zydus of final approval from the U.S. Food and Drug Administration (FDA) on its Abbreviated New Drug Application (ANDA) for generic Asacol(R) HD. Alternatively, if Zydus does not receive FDA approval of its generic Asacol(R) HD by July 1, 2016, Zydus will be permitted to launch an authorized generic version of Actavis' product beginning on July 1, 2016.

Similar Private Companies By Industry

Company Name Region
Concordia Pharmaceuticals Inc. United States
Pradama Inc. United States
Endo Finco Inc. United States
Corceuticals, LLC United States
K-V Discovery Solutions, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Zydus Pharmaceuticals (USA) Inc., please visit www.zydususa.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.